|Paratek Pharmaceuticals, Inc.
||Inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older
||Granted approval by the FDA
|Clovis Oncology, Inc.
||BRCA1/2-mutated mCRPC after androgen receptor (AR)-directed therapy and taxane-based chemotherapy
||Granted Breakthrough Therapy designation by the FDA
||Received “Study May Proceed Letter “ for IND application from the FDA; can initiate Phase II trials
||Relapsed or refractory multiple myeloma
||FDA approved supplemental New Drug Application to expand prescribing information
||BioCode® Gastrointestinal Pathogen Panel on BioCode® MDx-3000 molecular system
||Tests for 17 most common bacteria, viruses and parasites that cause infectious diarrhea
||Granted 510 (k) clearance by the FDA
|Eisai Co., Ltd.
||Partial-onset seizures in pediatric patients with epilepsy 4 years of age and older
||Granted approval by the FDA for an indication expansion
|Eli Lilly and Company
||Ultra Rapid Lispro (URLi)
||Type 1 and Type 2 diabetes
||Phase III clinical trials show met primary efficacy endpoint
|Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited
||ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, doxorubicin, prednisone)
||CD30-expressing peripheral T-cell lymphoma (PTCL), also known as mature T-cell lymphoma (MTCL)
||Phase III ECHELON-2 clinical trial met its primary endpoint
|Acorda Therapeutics, Inc.
||INBRIJA, investigational inhaled levodopa
||OFF periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen
||Releasing efficacy analysis from SPAN-PD, Phase III clinical trial
|Five Prime Therapeutics, Inc.
||Bemarituzumab (FPA144), an isoform-selective FGF receptor 2b (FGFR2b) antibody, with chemotherapy
||Advanced gastric cancer (GC) or gastroesophageal junction (GEJ) cancer
||First patient dosed in Phase III FIGHT pivotal trial
||Initiated Phase III clinical trial
||Type 1, 2 and 3 spinal muscular atrophy (SMA)
||Interim data from open-label clinical trials show increases in developmental motor milestones
|Veloce BioPharma, LLC
||VBP-926 (Povidone-Iodine) topical treatment
||Chemo-associated paronychia, or painful, inflamed nails, a chemo side effect
||Positive results of Phase IIb trial